Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Change in Inventory (2016 - 2025)

Historic Change in Inventory for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $17.5 million.

  • United Therapeutics' Change in Inventory rose 5486.73% to $17.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.7 million, marking a year-over-year increase of 1276.6%. This contributed to the annual value of $46.9 million for FY2024, which is 24485.29% up from last year.
  • As of Q3 2025, United Therapeutics' Change in Inventory stood at $17.5 million, which was up 5486.73% from $7.4 million recorded in Q2 2025.
  • Over the past 5 years, United Therapeutics' Change in Inventory peaked at $17.5 million during Q3 2025, and registered a low of -$5.7 million during Q1 2022.
  • Over the past 5 years, United Therapeutics' median Change in Inventory value was $7.0 million (recorded in 2023), while the average stood at $6.2 million.
  • The largest annual percentage gain for United Therapeutics' Change in Inventory in the last 5 years was 1380000.0% (2022), contrasted with its biggest fall of 35909.09% (2022).
  • Over the past 5 years, United Therapeutics' Change in Inventory (Quarter) stood at $100000.0 in 2021, then surged by 13800.0% to $13.9 million in 2022, then plummeted by 49.64% to $7.0 million in 2023, then surged by 65.71% to $11.6 million in 2024, then surged by 50.86% to $17.5 million in 2025.
  • Its last three reported values are $17.5 million in Q3 2025, $7.4 million for Q2 2025, and $11.2 million during Q1 2025.